Conditions & Wellness

Strong evidence from multiple RCTs and meta-analyses supports cannabinoid use for neuropathic and chronic pain reduction.

FDA-approved CBD (Epidiolex) for Dravet syndrome and Lennox-Gastaut syndrome. Strongest evidence base of any cannabinoid indication.

Moderate evidence for CBD in generalized anxiety disorder. THC shows dose-dependent effects — low doses may reduce anxiety; high doses may increase it.

Emerging clinical evidence supports cannabinoids for PTSD symptom reduction, particularly nightmares and hyperarousal. Several RCTs underway.

Short-term improvements in sleep onset and quality reported. Tolerance may develop with prolonged use. Evidence strongest for pain-related insomnia.

FDA-approved THC derivatives (dronabinol, nabilone) for CINV. Strong evidence base from decades of clinical use.

Nabiximols (Sativex) approved in multiple countries for MS-related spasticity. Consistent evidence across multiple trials.

Preclinical evidence is strong; human trials show promise for inflammatory conditions including IBD and arthritis. More RCTs needed.

Limited direct evidence for cannabis as an antidepressant. Some observational data; risk of worsening depression with heavy THC use noted.

Cannabis reduces intraocular pressure short-term, but duration is too brief for clinical utility. Not recommended as primary treatment.

THC stimulates appetite via CB1 receptors. FDA-approved for AIDS-related anorexia. Evidence for cancer cachexia is mixed.

Early-stage research shows potential for behavioral symptoms. Small trials show promise; larger RCTs are needed before clinical recommendations.